From a Lower-Tier Event in Astana to 2029: Trimetazidine, a Four-Year Ban, and the Quiet Audit of Tennis's Base Tier

The language of the bench was cold, almost that of an accountant. On the trimetazidine issue, the tribunal dismissed Parikshit Somani's defence with three adjectives: 'scientifically implausible', 'highly speculative', 'unconvincing'. Then came the announcement: a four-year suspension, running until September 2029. He will be thirty by then. It began with a sample given last year at a lower-tier event in Astana and ends on a fixed calendar date. Between those two points lives the tier of tennis nobody writes about — where a career-best doubles ranking is No. 256, where a player manages his own food and medication. The cameras move on, the ranking table does not update, and the case becomes a PDF.

I went back to the baseline in Sylhet to find what the highlight reel missed. Twenty-one years old when I started watching the tour closely, I have slowly turned from a man who watches matches into a man who watches ledgers. At a divisional meet in Sylhet I have seen players who had not competed in three years, who returned and could not find a hitting partner, who carried their own tape and ice in their own bag. These people are not stars, but the sport stands on them. Two and a half decades of watching have taught me one thing: the tier with the thinnest supervision is precisely the tier where the sanction is most absolute. Somani's case is the clearest proof of that sentence.

It helps to know who runs the machinery. Tennis's anti-doping and anti-corruption programme is operated by the International Tennis Integrity Agency, the ITIA, an independent body acting for the ITF, the ATP, the WTA and the Grand Slams. Under its umbrella sits the World Anti-Doping Code. Trimetazidine is a metabolic modulator, originally a cardiac medication, classified under S4 of the WADA Prohibited List and banned at all times, in and out of competition. It is a substance best known for returning again and again in food-contamination disputes.

According to the ITIA record, the sequence runs like this: a sample at a lower-tier event in Astana last year, a hearing before an independent tribunal in August, and the announcement of the ban on Wednesday. Somani is 26, and the only competitive figure cited is a career-best doubles ranking of No. 256. No singles ranking appears anywhere. What a case file omits is also information. A doubles peak of 256 at 26 places him well below the main-tour cut. What matters here is not the nature of the punishment but the space it leaves empty.

The door of this case rests on a single question: who holds the burden of proving contamination? Under the World Anti-Doping Code, it sits on the athlete's shoulders. He must not merely describe a credible route; he must prove the source. Somani's argument was food prepared by a family member. The tribunal said the argument does not hold scientifically. That is the point where a private case becomes a systemic trend.

A contamination defence today is no longer a question of truth but of documentation. When a family handles food and medication directly, an anti-doping vocabulary has a name for it: the 'family workshop' risk. Top-tier players keep food logs, supplement batch numbers, prescription records — not because they are more honest, but because they know evidence will be demanded later. Base-tier players keep none of this, because nobody ever taught them to. The standard of punishment is the same for everyone; the capacity to defend is not. That is the most uncomfortable truth in this file.

Look now at the scope of ineligibility. A ban does not stop at playing. Under the standard footprint, the athlete may not play, coach, or even attend ITF, ATP, WTA, Grand Slam or national-federation events. The natural exit into coaching, the route most fringe players take, is closed for four years. This is the standard WADA ineligibility boundary — a person moving from player to coach to administrator must first wait out the term.

The ranking arithmetic is harsher still. Protected Ranking exists for injury layoffs; it is generally unavailable for doping bans. Returning in 2029 means restarting from zero — qualifying draws, self-funded travel. Age thirty, a career ranking erased, four years of zero earnings. At this level, playing is roughly break-even; a four-year gap pushes the ledger straight into loss.

As judicial precedent, the case is stitched to a single thread. Same substance, same four-year outcome — the comparison with Kamila Valieva is natural, and the tribunal's posture is converging. Caution is needed: the similarity between the Valieva matter and Somani's lies in defence strategy, not in facts. Sun Yang's 2026 trimetazidine case is cited, but that too is a substance parallel, not a procedural one. The comparison raises news value, not legal weight.

A counter-intuitive relationship is at work between headline and harm. Four years sounds immense; yet for a player ranked No. 256 in doubles the competitive loss is close to zero, while the professional loss is close to total. Those whose cases are most discussed are often those with the least to lose; those with the most to lose rarely make a headline. Somani's case sits exactly between those two poles.

From an industry standpoint there is no market tremor. The prize-money ecosystem is neutral, the Grand Slam business is neutral, sponsorship and capital flows are neutral. What remains is a governance signal: monitoring is working at the very base of the pyramid, and each time a trimetazidine food-contamination argument arrives, patience is shorter. That is the actual news, not the name.

Bangladesh becomes relevant precisely here. The real market for tennis in this country is not a television bonanza; it is a Davis Cup tie, the ITF junior events in Dhaka, the small circles of domestic tournaments. The transfer window is not a market; it is a mirror held to hope. What that mirror shows in tennis is the sponsor-television-media loop, where wire copy of foreign Grand Slams gets printed and nobody keeps the ledger of the court next door. There is no room in that loop for anti-doping education.

Our problem is not doping; our problem is administrative silence. The BTF was founded in 2026, joined the ITF in 2026, debuted in the Davis Cup in 2026, reached an Asia/Oceania semi-final in 2026 — and then declined into Group V. This year's junior J30 events and Zarif Abrar's 2026 junior title are small system signals, not miracles. The question is who builds the link between those signals and anti-doping education. Who will teach the BKSP girls or the teenagers at divisional meets to keep supplement batch numbers?

When the stadiums emptied, I heard the game. In the silent year I spoke to players at the Ramna National Tennis Complex who had lost their only income and sat at home. What I understood then still holds: in this sport a person's entire profession rests on a small tube, and when it breaks he is alone. My sense is that no party lied in Somani's case, and yet a player has effectively been finished.

What to watch from here: whether an appeal is filed at the Court of Arbitration for Sport; how the ITIA's published sanction list records the term and its start date; whether the Indian federation issues a statement or a support plan; and whether the language of future trimetazidine tribunals hardens further. Those four signals will describe the anti-doping environment of the next two years.

The final question is not about doping but about administration. Before the next junior batch steps on court, will we teach them this much — knowing what is inside your supplement bottle is your own responsibility, because when proof is demanded, nobody will answer for you.